|Bid||54.23 x 900|
|Ask||54.42 x 900|
|Day's range||52.74 - 55.30|
|52-week range||41.33 - 277.80|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||183.40|
Novavax (NASDAQ: NVAX) investors are no strangers to tragedy. On Feb. 9 in 2021, shares of the coronavirus vaccine developer hit their all-time high of $331.68. Are longtime shareholders doomed to heavy losses forever, or will Novavax return to its glory days?
A turbulent market didn't scare successful money managers away from buying shares in these fast-paced companies.
Novavax disappointed investors when its regulatory submissions fell behind. Now, all eyes are on Novavax's next step: winning authorization in the U.S. Could this nudge the stock out of its slump -- and even turn it into a multibagger? Novavax reported revenue of $704 million and net income of $203 million.